N/A
N=10
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
Schizophrenia
Bottom Line
View on ClinicalTrials.gov: NCT00225498 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcome: Primary: Working Memory — 44.8 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- ziprasidone vs risperidone or olanzapine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwell Health
- Primary completion
- Oct 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Working Memory |
44.8 | — |
Summary
Ziprasidone is a newer drug intended for the treatment of the symptoms of schizophrenia. This new drug may have an added benefit of being able to help with some of the difficulties in problem solving and memory that many patients with schizophrenia experience. The present study wants to look at ziprasidone and two other drugs frequently used to treat the symptoms of schizophrenia (risperidone and olanzapine) to see if problem solving and memory get better with ziprasidone treatment. Moreover, we will look at symptoms and how they change with treatment.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder
- Ages 18 - 50
- Ability to provide written informed consent
- Brief Psychiatric Rating Scale (BPRS) total score > 40 and Clinical Global Impressions (CGI) > 4 (moderately ill) and/or intolerant to current antipsychotic drug treatment
Exclusion Criteria
- History of prior treatment with ziprasidone
- History of medical condition that contraindicates ziprasidone treatment
- Treatment with depot antipsychotic medication in past 3 months
- Current diagnosis of alcohol or psychoactive substance dependence
- Impaired ability to provide written informed consent
Data sourced from ClinicalTrials.gov (NCT00225498). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.